0001295345-17-000137.txt : 20170515 0001295345-17-000137.hdr.sgml : 20170515 20170515121007 ACCESSION NUMBER: 0001295345-17-000137 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170515 DATE AS OF CHANGE: 20170515 EFFECTIVENESS DATE: 20170515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Emerald Medical Applications Corp. CENTRAL INDEX KEY: 0000797542 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 680080601 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-15746 FILM NUMBER: 17842555 BUSINESS ADDRESS: STREET 1: 7 IMBER STREET CITY: PETACH TIKVA STATE: L3 ZIP: 4951141 BUSINESS PHONE: 97237444505 MAIL ADDRESS: STREET 1: 7 IMBER STREET CITY: PETACH TIKVA STATE: L3 ZIP: 4951141 FORMER COMPANY: FORMER CONFORMED NAME: ZAXIS INTERNATIONAL INC DATE OF NAME CHANGE: 19950916 FORMER COMPANY: FORMER CONFORMED NAME: INFERGENE CO DATE OF NAME CHANGE: 19920703 NT 10-Q 1 mrla_nt.htm LATE NOTIFICATION

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

EMERALD MEDICAL APPLICATIONS CORP.
(Full Name of Registrant)

FORM 12b-25

NOTIFICATION OF LATE FILING

SEC FILE NUMBER: [0-15476]

(Check One): [  ]Form 10-K [ ] Form 20-F [ ]Form 11-K [X] Form 10Q [  ] Form N-SAR [ ]

For Period Ended:
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-QSB
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRATION INFORMATION

Emerald Medical Applications Corp.
7 Imber Street, Petach Tivka, 4951141 Israel
Address of  Principal Executive Office (Street and Number)

PART II - RULE 12b-25(b)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

[X] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

[X] (b) The subject annual report on Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date.

PART III - NARRATIVE

The Registrant's annual report on Form 10-K could not be filed within the prescribed time period because the Registrant encountered delays in preparing its financial statements.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification.

Alimi Ahmed, CEO
(Name)
+(972) 3-744-4505
(Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

[X] Yes [ ] No

(3) Is it anticipated that any significant changes in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[  ] Yes [X] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

____________________________________________________

Emerald Medical Applications Corp.
Name of Registrant as Specified in Charter

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

By: Alimi Ahmed, CEO
Date: May 15, 2017
By /s/ Alimi Ahmed